Check out the latest episode of Raising Biotech where our CEO, Craig Thompson, and Dr. Karl Kieburtz delve into the innovative strategies we're employing to create precision therapeutics for Parkinson's disease using our cutting-edge NETSseq platform.
Healthcare & Business Journalist | Editor | Writer | Podcaster | Moderator | Pharma/Biotech and Healthcare Sectors
The next episode of Raising Biotech is up, this time looking at the CNS and Parkinson's disease with Cerevance. In this episode, CEO Craig Thompson joins the podcast to speak about Cerevance's unique mission and use of its NETSseq platform to develop more targeted precision medicines for CNS diseases, particularly targeting the GPR6 receptor in Parkinson's disease. Craig speaks about the company's origins, its unique financing journey (close to $200 million since inception), what drove him to join during the company's growth phase, plans for upcoming clinical trials as well as a potential near-term IPO. Expert neurologist Dr Karl Kieburtz, the founder of advisory firm Clintrex and Professor in Neurology at the University of Rochester Medical School gives us his take on the general Parkinson's unmet need and Cerevance's unique mission to go beyond targeting the dopaminergic pathway. As a company advisor, Karl has a good understanding of the NETSseq platform and how targeting GPR6 might make a meaningful difference for Parkinsons' patients, but he also illustrates what challenges Cerevance will need to carefully navigate to avoid a crowded Parkinson's graveyard. Listen (and find time stamps) here ⏯️: Apple: https://lnkd.in/eReD-fwt Spotify: https://lnkd.in/e-7_ChQu This episode is proud to be partnered with Mindgram - a research tool powered by AI serving the global biopharma community. Raising Biotech listeners are able to get an exclusive free trial (link in show notes). GV (Google Ventures) Gates Frontier (Bill Gates), Lightstone Ventures, Agent Capital Bioluminescence Ventures Double Point Ventures MQB Partners Liferock Ventures Dolby Family Ventures UPMC Enterprises Casdin Capital, LLC #biotech #venturecapital #parkinsonsdisease #CNS
I help craft the stories that bring your bioscience company and strong development partners together
2moWonderful interview by Surani Fernando and insights by Craig Thompson and Karl Kieburtz. Props for the company's research!